The premise underlying the executive order signed by President Trump on June 24, 2019, is that if patients were informed about what hospitals and providers are charging for their services, then they would be able to shop around for better deals.
A diagnosis of type 1 diabetes (T1D) is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
Study participants in the lowest-income study sites experienced worse blood pressure control and poorer cardiovascular outcomes despite standardized treatment protocols and having similar baseline blood pressure as participants in the highest income areas.
The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.
Medical professionals need to express their support for child advocacy programs to ensure that medical care is free from coercion and undue influences and is actually in the best interest of the child.
Compared with rural counties with high broadband availability, rural counties with low broadband availability had 34% fewer telemedicine visits per capita.
A section on the use of technology in the management of diabetes has been added to the American Diabetes Association Standards of Medical Care in Diabetes.
Deep natural language processing may be able to estimate the presence of active cancer, cancer worsening or progression, and cancer improvement or response from radiologic reports.
High emotional exhaustion and high depersonalization among resident physicians were both associated with more unfavorable attitudes toward black people.
The FDA has granted 510(k) clearance to binx io (binx health) for women’s health, a molecular point-of-care diagnostic testing platform for detecting chlamydia and gonorrhea in approximately 30 minutes.
Past coverage expansions were associated with little or no change in society-wide hospital use; increases in groups who gained coverage were offset by reductions among others.
Treatment of atopic dermatitis should generally follow a “safety first” approach with effective treatment options rather than avoiding nearly all possible treatment modalities.
According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.
